Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome

American Journal of Pathology

Volumn 176, Issue 6, 2010, Pages 2911-2920

  Khramtsov, Andrey I ^a   Khramtsova, Galina F ^a   Tretiakova, Maria ^a   Huo, Dezheng ^a   Olopade, Olufunmilayo I ^a   Goss, Kathleen H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VIMENTIN; WNT PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER INVASION; CARCINOMA IN SITU; CELLULAR DISTRIBUTION; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR GROWTH; AGED; ANIMAL; BASAL CELL CARCINOMA; BREAST TUMOR; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MOUSE; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ADULT; AGED; ANIMALS; BETA CATENIN; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASMS, BASAL CELL; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SURVIVAL RATE; WNT PROTEINS;

EID: 77953183234     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091125     Document Type: Article

References (50)

1. Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R: The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 50:649-657
2. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625
3. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480
4. Hatsell S, Rowlands T, Hiremath M, Cowin P: Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003, 8:145-158
5. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA: Dysregulation of Hedgehog. Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 2009, 24:385-398
6. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP: Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001, 3:793-801
7. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000, 97:4262-4266
8. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006, 66:5487-5494
9. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS: c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000, 36:313-325
10. Dillon DA, D'Aquila T, Reynolds AB, Fearon ER, Rimm DL: The expression of p120ctn protein in breast cancer is independent of alphaand beta-catenin and E-cadherin. Am J Pathol 1998, 152:75-82 (Pubitemid 28028048)
11. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, Pignatelli M: Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 2001, 27:31-36
12. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL: E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998, 185:262-266
13. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002, 196:145-153
14. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM: Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001, 193:433-441
15. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM: Expression of S100A4. E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 2002, 87:1281-1286
16. Fadare O, Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 2008, 5:149-159
17. Bryan BB, Schnitt SJ, Collins LC: Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006, 19:617-621
18. Mohsin SK, O'Connell P, Allred DC, Libby AL: Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 2005, 90:249-256
19. Elston EW, Ellis IO: Method for grading breast cancer. J Clin Pathol 1993, 46:189-190
20. Fan F, Thomas P: Tumors of the breast. Cancer Grading Manual 2007, 75-81
21. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752
22. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96-108
23. Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, Orenstein J, Bayerl J, Becich MJ, Dhir R, Datta MW: Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 2007, 38:113-121
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847
25. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990, 50:7057-7061 (Pubitemid 20361113)
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145 (Pubitemid 350003059)
27. Dabbs DJ, Chivukula M, Carter G, Bhargava R: Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006, 19:1506-1511
28. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53
29. Hedeker D, Gibbons RD: A random-effects ordinal regression model for multilevel analysis. Biometrics 1994, 50:933-944
30. Hao X, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC: Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch 1997, 431:167-172
31. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD: Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002, 161:1087-1097 (Pubitemid 34988396)
32. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124
33. McCarthy A, Savage K, Gabriel A, Naceur C, Reis-Filho JS, Ashworth A: A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007, 211:389-398
34. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ, Wang Y: Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS ONE 2009, 4:e4968
35. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334
36. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA: Small-molecule antagonists of the oncogenic TCF/beta-catenin protein complex. Cancer Cell 2004, 5:91-102
37. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M: A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci U S A: 2004, 101:12682-12687
38. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203
39. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997
40. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 2003, 63:2658-2664 (Pubitemid 36605210)
41. Woodward WA, Chen MS, Behbod F, Rosen JM: On mammary stem cells. J Cell Sci 2005, 118:3585-3594
42. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA: 2007, 104:618-623
43. Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA, Rosen JM: Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007, 120:468-477
44. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL: Beta-catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004, 100:2084-2092
45. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR: Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999, 80:1046-1051
46. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH: Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000, 21:1935-1940
47. Herter P, Kuhnen C, Muller KM, Wittinghofer A, Muller O: Intracellular distribution of beta-catenin in colorectal adenomas, carcinomas and Peutz-Jeghers polyps. J Cancer Res Clin Oncol 1999, 125:297-304
48. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728
49. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 2006, 295:2492-2502
50. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG: Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008, 14:4038-4044